SCHEMBL2625322

SCHEMBL2625322

CCCN1Cc2c(C)nc(-c3ccc(C)cc3)nc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 5/20 0.40
SIRT1 Q96EB6 1/20 0.40
ALDH1A1 P00352 3/20 0.38
GAA P10253 2/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 1/20 0.38
ADORA3 P0DMS8 2/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
CYP1A2 P05177 1/20 0.35
PTGS1 P23219 1/20 0.34
KCNH2 Q12809 1/20 0.34
DPP4 P27487 1/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
BLM P54132 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2625330 0.88 TLR9 (0.40) TDP2SIRT1ALDH1A1KDM4ELMNA
SCHEMBL10220350 0.72 HTR1A (0.39) ALDH1A1GAALMNAADORA3ADORA2A
SCHEMBL2625328 0.72 KCNH2 (0.39) LMNAADORA3CYP1A2KCNH2MEN1
SCHEMBL2625326 0.69 TLR9 (0.39) LMNAKCNH2L3MBTL1
SCHEMBL2625321 0.69 DRD2 (0.43) LMNAKCNH2MAPTL3MBTL1TP53
SCHEMBL2625325 0.68 HSF1 (0.35) TDP2ALDH1A1KDM4ELMNAADORA3
SCHEMBL2625327 0.68 KCNH2 (0.36) TDP2SIRT1ALDH1A1KDM4ELMNA
SCHEMBL13423651 0.62 TDP2 (0.39) TDP2SIRT1ALDH1A1KDM4ELMNA
Imrecoxib SCHEMBL3034253 0.61 PTGS2 (0.76) PTGS1
SCHEMBL12082379 0.60 ALDH1A1 (0.44) SIRT1ALDH1A1GAAKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165313-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2012-06-28 US disclosed
US-8163763-B2 Pyrimidine compounds, compositions and methods of use GENENTECH, INC. (US) 2012-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165313-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE MTOR, TYMS, DTYMK TDP2 571/4885SIRT1 2795/4885ALDH1A1 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.